Shares of Ocugen (NASDAQ: OCGN) were jumping 13.9% higher as of 3:28 p.m. ET on Wednesday. The big gain came after data from a third-party study showed a promising immune response against variants of concern from COVID-19 vaccine Covaxin for up to six months.
The results from the study haven't been peer-reviewed yet. However, they appear to be encouraging. The data showed that Covaxin achieved an immune response similar to that of natural COVID-19 infection in terms of antibody levels as well as levels of memory B cells and CD4+ T cells. This data stands in stark contrast to the waning efficacy observed with messenger RNA (mRNA) vaccines with the delta variant.
Image source: Getty Images.
Source Fool.com